Standout Papers

Safety and efficacy of mosunetuzumab, a bispecific antibody, in patients with relapsed or refractory follicular lymphoma:... 2022 2026 2023 2024222
  1. Safety and efficacy of mosunetuzumab, a bispecific antibody, in patients with relapsed or refractory follicular lymphoma: a single-arm, multicentre, phase 2 study (2022)
    Lihua E. Budde, Laurie H. Sehn et al. The Lancet Oncology

Immediate Impact

5 by Nobel laureates 9 from Science/Nature 63 standout
Sub-graph 1 of 22

Citing Papers

Novel strategies to manage CAR-T cell toxicity
2025 Standout
The present and future of bispecific antibodies for cancer therapy
2024 Standout
5 intermediate papers

Works of Antonia Kwan being referenced

Safety and efficacy of mosunetuzumab, a bispecific antibody, in patients with relapsed or refractory follicular lymphoma: a single-arm, multicentre, phase 2 study
2022 Standout
An Individualized Risk Mitigation Approach for Safety: Experience from the Mosunetuzumab (CD20/CD3 Bispecific Antibody) Development Program in Relation to Neurotoxicity Risk
2019
and 2 more

Author Peers

Author Last Decade Papers Cites
Antonia Kwan 605 646 364 40 1.4k
Diana F. Hausman 576 467 125 40 1.5k
Peter von Wussow 313 643 236 43 1.2k
Zhong-Jun Xia 1021 538 749 50 1.5k
Laura K. Aguilar 766 531 131 44 1.5k
Lars Sternås 851 509 272 55 1.6k
María Francisca González‐Escribano 162 707 137 62 1.6k
Marie‐Christine Jacob 321 555 324 66 1.3k
Laura Caggiari 423 355 406 62 1.3k
Joop van Baarlen 331 216 418 43 1.3k
Jean‐Marc Limacher 755 472 160 44 1.4k

All Works

Loading papers...

Rankless by CCL
2026